Human Genome unlikely to attract a higher bid - BMO

(Reuters) - There is a high risk of GlaxoSmithKline dropping its pursuit of Human Genome Sciences Inc , BMO Capital Partners said, adding that a rival bid for the biotechnology company also seemed unlikely. The brokerage, which downgraded Human Genome stock to "market perform" from "outperform", said chances of the company attracting a better price were low

Read more ...